NCT02039960View on ClinicalTrials.gov

PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Depressive Disorder, Major

Interventions

DRUG

Bupropion

Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.